Figure 5.
The reinforcing effects of vaporized CANTHC require CB1 receptor stimulation. Mean (A) active nose-poke responses for CANTHC and (B) CANTHC vapor deliveries following systemic administration of the CB1R antagonist AM251 (0, 1, or 3 mg/kg, i.p.). Mean (C) active nose-poke responses for CANCBD and (D) CANCBD vapor deliveries following systemic administration of the CB1R antagonist AM251 (0, 1, or 3 mg/kg, i.p.). Data are depicted as a percentage of baseline from the preceding mock injection day. p ≤ 0.05. *Significant differences between CANTHC and VEH groups.